Rifapentine: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
m Changed protection level for "Rifapentine" ([Edit=Allow only autoconfirmed users] (expires 21:40, 2 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 21:40, 2 January 2014 (UTC)))
Chetan Lokhande (talk | contribs)
nocaptcha
4,484 edits
No edit summary
Line 1: Line 1:
{{drugbox
| IUPAC_name = 3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
| image = Rifapentine.png
| CAS_number = 61379-65-5
| ATC_prefix = J04
| ATC_suffix = AB05
| ATC_supplemental =
| PubChem = 5462354
| DrugBank = APRD01217
| C=47 | H=64 | N=4 | O=12
| molecular_weight = 877.031 g/mol
| bioavailability = increases when administered with food
| protein_bound =
| metabolism =
| elimination_half-life =
| pregnancy_category =
| legal_status =
| routes_of_administration =
}}
{{SI}}


__NOTOC__
{{Rifapentine}}
{{CMG}}; {{AE}} {{chetan}}


'''Rifapentine''' (marketed under the brand name '''Priftin''' by [[Aventis]]) is an [[antibiotic]] drug used in the treatment of [[tuberculosis]].
==Overview==


==History==
==Category==
Rifapentin was first synthesized in 1965 by the same company that produced [[rifampin]]. The drug was approved by the [[Food and Drug Administration]] (FDA) in June 1998.
Antimycobacterial
==US Brand Names==
Priftin®
==FDA Package Insert==
'''[[Rifapentine description|Description]]'''
'''| [[Rifapentine clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Rifapentine microbiology|Microbiology]]'''
'''| [[Rifapentine indications and usage|Indications and Usage]]'''
'''| [[Rifapentine contraindications|Contraindications]]'''
'''| [[Rifapentine warnings and precautions|Warnings and Precautions]]'''
'''| [[Rifapentine adverse reactions|Adverse Reactions]]'''
'''| [[Rifapentine overdosage|Overdosage]]'''
'''| [[Rifapentine clinical studies|Clinical Studies]]'''
'''| [[Rifapentine dosage and administration|Dosage and Administration]]'''
'''| [[Rifapentine compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Rifapentine directions for use|Directions For Use]]'''
'''| [[Rifapentine how supplied|How Supplied]]'''
'''| [[Rifapentine labels and packages|Labels and Packages]]'''


==External links==
==Mechanisms of Action==
*Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, et al. 2007. Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model. [[PLoS Medicine]] Vol. 4, No. 12, e344 doi:10.1371/journal.pmed.0040344 [http://dx.doi.org/10.1371/journal.pmed.0040344]


[[Category:Rifamycin antibiotics]]
==References==
{{Reflist|2}}


 
[[Category:Antibiotics]]
{{WH}}
[[Category:Wikinfect]]
{{WS}}

Revision as of 03:06, 6 January 2014


Rifapentine
FDA Package Insert (PRIFTIN®)
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Category

Antimycobacterial

US Brand Names

Priftin®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages

Mechanisms of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Rifapentine&oldid=925681"